Business Context and Reporting Period
Company: Champions Oncology, Inc. (CSBR)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three months ended July 31, 2026
Business Overview: The Company is a technology-enabled research organization providing drug discovery and development services via its TumorGraft Technology Platform (PDX models). It operates in a single segment offering pharmacology services, data licensing, and bioinformatics software (Lumin).
Key Financial Metrics
| Metric (in thousands) | Q1 2027 (Ended July 31, 2026) | Q1 2026 (Ended July 31, 2025) |
|---|---|---|
| Oncology Revenue | $15,232 | $13,995 |
| Cost of Oncology Revenue | $7,534 | $7,995 |
| Gross Profit | $7,698 | $6,000 |
| Gross Margin | 50.5% | 42.9% |
| Operating Loss | $(409) | $(527) |
| Net Loss | $(426) | $(466) |
| Cash and Cash Equivalents | $4,358 | $10,325 (End of prior period) |
| Working Capital | $563 | Not explicitly stated (Calculated: ~$(703)) |
| Accumulated Deficit | $(81,493) | $(80,358) |
Liquidity: The Company reported cash of $4.4 million and working capital of $563,000 as of July 31, 2026. Management believes current cash and expected operating cash flows are sufficient to fund operations through at least September 2027.
Material Changes vs. Prior Period
- Revenue Growth: Oncology revenue increased 8.8% to $15.2 million, driven by a 7.0% increase in pharmacology services and a 187% increase in TOS data license revenue ($893k vs $311k).
- Expense Increases:
- Sales and Marketing: Increased 66.6% to $3.1 million due to commercial organization expansion.
- Research and Development: Increased 12.6% to $2.3 million, primarily due to higher stock-based compensation for the Corellia subsidiary.
- Cost of Revenue: Decreased 5.8% to $7.5 million due to lower outsourced lab costs, despite higher royalty expenses.
- Profitability: Operating loss narrowed by 22.4% to $409k, and net loss decreased to $426k, reflecting improved gross margins and revenue growth outpacing certain cost increases.
- Cash Flow: Net cash used in operating activities was $492k, a reversal from the $600k provided in the prior year period, driven by the net loss and changes in working capital (specifically a decrease in accounts payable and increase in accounts receivable).
- Lease Obligations: A significant lease amendment in June 2026 extended the Rockville, MD facility lease to 2037, adding $6.3 million in operating right-of-use assets and liabilities.
Outlook, Risks, and Management Commentary
- Strategic Focus: Management is shifting focus away from flow cytometry and Lumin SaaS (Other TOS revenue decreased) toward core research services and data licensing.
- Capital Resources: While current liquidity is deemed adequate for 12+ months, the Company has an accumulated deficit of $81.5 million. Future capital raises may be necessary, with no assurance of success or terms.
- Stock-Based Compensation: Significant non-cash expense ($766k for the quarter) related to equity incentives, particularly for the Corellia subsidiary. $3.9 million of unrecognized stock-based compensation remains.
- Risks: As a smaller reporting company, the filing does not detail specific risk factors but references the 2026 Annual Report. General risks include economic uncertainty, supply chain disruptions, and the inability to raise additional capital.
- Legal: No pending legal proceedings known to management.
Investor Verification Checklist
- Liquidity Runway: Verify the sufficiency of the $4.4 million cash balance against the $492k quarterly operating cash burn and the $81.5 million accumulated deficit.
- Revenue Quality: Assess the sustainability of the 187% jump in data license revenue and the decline in "Other TOS" revenue as the company pivots strategy.
- Lease Commitments: Review the impact of the new $6.3 million operating lease liability on future cash flow obligations and the extended lease term through 2037.
- Stock-Based Compensation: Monitor the $3.9 million in unrecognized stock-based compensation and its potential impact on future earnings.
- Working Capital Trends: Investigate the $1.4 million decrease in accounts payable and $414k increase in accounts receivable, which contributed to negative operating cash flow despite revenue growth.